...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: How & who comes up with valuations?

I'll add we see valuations based on success e.g the billions of dollars per year in each perspective market space , surely given the success to date with tumors etc there would have to be some value added even at this stage - add in the low toxicity etc - anyway its sliced the value with current potential/upside just doesn't add up for me.

Share
New Message
Please login to post a reply